HEALTHY U CHIP

PRIOR AUTHORIZATION REQUEST FORM

Zoryve™

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior Authorization Department at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: 385-425-5094

Disclaimer: Prior Authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: ☐ Zoryve™ 0.3% cream, ☐ Zoryve™ 0.3% foam

Dosing/Frequency:_____

If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
SEBORRHEIC DERMATITIS			
1. Is the request made by, or in consultation with, a dermatologist, allergist or immunologist?	☐	☐	
2. Does the member have moderate to severe seborrheic dermatitis with an Investigator Global Assessment (IGA) of 3 or 4?	☐	☐	**Please provide documentation**
3. Does the member take any of the following medications? • Biologic DMARDs [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Stelara (ustedkinumab), Orencia (abatacept)]; OR • Janus Kinase Inhibitors [e.g., Xeljanz (tofacitinib), Oluminat (baricitinib), Rinvoq (upacitinib)]; OR • Phosphodiesterase 4 (PDE4) inhibitors [e.g., Otezla (apremilast)]	☐	☐	
4. Does documentation show failure or contraindication to ALL of the following? • topical antifungal • a medium to high potency corticosteroids (e.g., triamcinolone acetonide 0.1%, mometasone furoate 0.1%,	☐	☐	**Please provide documentation**

betamethasone dipropionate 0.05%, desoximetasone 0.05%); AND • a topical calcineurin inhibitor such as pimecrolimus or tacrolimus; AND • phototherapy; AND • oral antifungal			
PSORIASIS			
1. Is the request made by, or in consultation with, a dermatologist?	☐	☐	
2. Does the member have a diagnosis of psoriasis?	☐	☐	**Please provide documentation**
3. Does the member take any of the following medications? • Biologic DMARDs [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Stelara (ustedkinumab), Orencia (abatacept)]; OR • Janus Kinase Inhibitors [e.g., Xeljanz (tofacitinib), Oluminat (baricitinib), Rinvoq (upacitinib)]; OR • Phosphodiesterase 4 (PDE4) inhibitors [e.g., Otezla (apremilast)]	☐	☐	
4. Is the affected area less than 20% of body surface area?	☐	☐	**Please provide documentation**
5. For eyelids, face, neck and genital areas, does documentation show failure or contraindication to topical calcineurin inhibitor, such as pimecrolimus or tacrolimus?	☐	☐	**Please provide documentation**
6. Does documentation show failure or contraindication to ALL of the following? • two medium to high potency corticosteroids (e.g., triamcinolone acetonide 0.1%, mometasone furoate 0.1%, betamethasone dipropionate 0.05%, desoximetasone 0.05%); AND • a topical calcineurin inhibitor such as pimecrolimus or tacrolimus; AND • phototherapy	☐	☐	**Please provide documentation**
REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	☐	☐	
2. Does the member show a continued medical need for the therapy?	☐	☐	**Please provide documentation**
3. Has the therapy been tolerable and effective?	☐	☐	**Please provide documentation**
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			

Additional information:
Physician Signature:

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy: PHARM-CHIP-147
Origination Date: 07/01/2024
Reviewed/Revised Date: 11/13/2024
Next Review Date: 11/13/2025
Current Effective Date: 12/01/2024